VIR vs ADMA vs REGN vs GRFS vs ALNY

For growth investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger pick with 65. 2% revenue growth year-over-year, versus -7. 6% for Vir Biotechnology, Inc. (VIR). Grifols, S. A. (GRFS) offers the better valuation at 12. 0x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Vir Biotechnology, Inc. (VIR) a "Buy" — based on 12 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Grifols, S.

A. (GRFS) is the cheapest at 12. 0x versus Alnylam Pharmaceuticals, Inc. at 127. 0x. On forward P/E, Grifols, S. A. is actually cheaper at 9. 4x.

Over the past 5 years, ADMA Biologics, Inc.

(ADMA) delivered a total return of +386. 8%, compared to -78. 4% for Vir Biotechnology, Inc. (VIR). Over 10 years, the gap is even starker: ALNY returned +410. 4% versus GRFS's -35. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Alnylam Pharmaceuticals, Inc.

(ALNY) is the lower-risk stock at 0. 74β versus Vir Biotechnology, Inc. 's 2. 04β — meaning VIR is approximately 175% more volatile than ALNY relative to the S&P 500. On balance sheet safety, Regeneron Pharmaceuticals, Inc. (REGN) carries a lower debt/equity ratio of 9% versus 162% for Alnylam Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Alnylam Pharmaceuticals, Inc.

(ALNY) is pulling ahead at 65. 2% versus -7. 6% for Vir Biotechnology, Inc. (VIR). On earnings-per-share growth, the picture is similar: Alnylam Pharmaceuticals, Inc. grew EPS 206. 9% year-over-year, compared to -25. 9% for ADMA Biologics, Inc.. Over a 3-year CAGR, ALNY leads at 53. 0% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -638. 9% for Vir Biotechnology, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADMA leads at 37. 5% versus -682. 7% for VIR. At the gross margin level — before operating expenses — REGN leads at 85. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Grifols, S.

A. (GRFS) trades at 9. 4x forward P/E versus 39. 9x for Alnylam Pharmaceuticals, Inc. — 30. 6x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ADMA: 147. 9% to $21. 00.

In this comparison, GRFS (2.

6% yield), REGN (0. 5% yield) pay a dividend. VIR, ADMA, ALNY do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alnylam Pharmaceuticals, Inc.

(ALNY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 74), +410. 4% 10Y return). Vir Biotechnology, Inc. (VIR) carries a higher beta of 2. 04 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ALNY: +410. 4%, VIR: -34. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VIR is a small-cap quality compounder stock; ADMA is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; GRFS is a small-cap deep-value stock; ALNY is a mid-cap high-growth stock. GRFS pays a dividend while VIR, ADMA, REGN, ALNY do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.